Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated ...

随着靶向、免疫等治疗手段的兴起，晚期胃癌的一线治疗手段日益丰富，然而二线治疗领域却长期面临研究进展缓慢、治疗选择有限的困境。而 FRUTIGA ...

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

Background: The impact that smoking cigarettes has on the characteristics and survival of patients with non-small cell lung cancer (NSCLC) is disputed. Methods: A retrospective cohort study using ...

Some that may be used are Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab), Zaltrap (ziv-aflibercept), Cyramza (ramucirumab), Stivarga (regorafenib), and Fruzaqla (fruquintinib).

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...